Sun Pharmaceutical Industries, a leading Indian multinational pharmaceutical company, is expecting a positive trajectory for the current fiscal year. According to the company’s Managing Director, Dilip Shanghvi, Sun Pharma anticipates achieving a robust high single-digit increase in revenue.
This positive outlook comes on the heels of a successful FY24, where the company reported a consolidated total revenue from operations of Rs 48,497 crore, demonstrating a significant increase from Rs 43,886 crore in FY23.
Shanghvi, during an analyst call, expressed confidence in the company’s future, stating, “We expect high single-digit consolidated top line growth for FY25. All our businesses are positioned for growth.” He acknowledged that the company will be investing heavily in product launches and R&D activities during the current fiscal year, but these investments are seen as essential for long-term success.
Sun Pharma’s optimism is a welcome sign for investors in the Indian pharmaceutical sector.
The company’s strong market share and focus on innovation position it well for continued growth in the coming year.
